 | coronary thrombosis Thrombosis is the formation of a clot or thrombus within the lumen of a blood vessel, obstructing the flow of blood through the circulatory system. Thromboembolism is a general term describing both thrombosis and its main complication which is embolisation. When a thrombus occupies more than 75% of surface area of the lumen of an artery, blood flow to the tissue supplied is reduced enough to cause symptoms because of decreased oxygen (hypoxia) and accumulation of metabolic products like lactic acid. More than 90% of obstruction can result in anoxia, the complete deprivation of oxygen, and infarction, a mode of death of cells. |
 | Deep Vein Thrombosis This condition causes more deaths each year than AIDS and breast cancer combined. |
 | BLACK VEGAS deep vein thrombosis the video to Adelaide band Black Vegas' number one underground cult smash hit |
 | Health Watch: Deep Vein Thrombosis Did you know more Americans die annually from deep vein thrombosis (DVT)/pulmonary embolism (PE) than from breast cancer and AIDS combined? Yet 74 percent of Americans have little or no awareness of DVT, according to a national survey sponsored by the American Public Health Association. In this week's show we talk to a good friend, Heather Morelli, who was recently diagnosed with DVT /PE. She gives a first-hand account of how she developed blood clots in her leg and how they traveled to her lungs. Find out what may have caused them and her ideas about what you can do if it happens to you or someone you know. Watch WhitneyandWyatt.com any time you want to be informed, inspired and entertained! |
 | alammouri 4_deep venous thrombosis presentation the best dentist Deep venous thrombosis presntation |
 | Mr Azariah Deep Vein Thrombosis This is Mr Azariah of Haydon School Science department instructing passengers on long-haul flights of the dangers and risk factors of Deep Vein Thrombosis (DVT) |
 | Histopathology Popliteal vein--Thrombosis Histopathology Popliteal vein--Thrombosis |
 | deep venous thrombosis まいどyanchangです。 くわしくはhttp://blog.livedoor.jp/yanchang/?b log_id=2439666 にて。 |
 | Deep-Vein Thrombosis Awareness PSA featuring Tony Gwynn Deep-Vein Thrombosis Awareness PSA featuring Tony Gwynn 31 sec - Nov 20, 2006 This was filmed in California in 2005 in support of DVT Blood Clots: Know The Stats. Know Your Risk., a national education campaign to help raise awareness of Deep-Vein Thrombosis (DVT) blood clots, which affect up to 300,000 people in the United States each year. Complications of DVT, including pulmonary embolism (PE), kill up to 200,000 people annually in the United States -- more than AIDS and breast cancer combined. More information on DVT blood clots can be found at www.DVT.net |
 | Running Raw: Deep Vein Thrombosis In this episode of the Running Raw Project: As Tim gets ready to head to the National Mtn. Running Championships in NH, he does a little research on the effects of flying on athletic performance. |
 | Deep Vein Thrombosis-Mayo Clinic John Heit, M.D., a cardiovascular physician at Mayo Clinic, received today a $1.1 million grant from the National Institutes of Health for its Genes, Environment and Health Initiative. Dr. Heit's grant will be used to study the genome-wide association of venous thrombosis (blood clots in the veins). Deep vein thrombosis is a blood clot in a vein — a blood vessel that returns oxygen-depleted blood to your heart. These clots are different from those that form in an artery — a blood vessel that carries oxygen-rich blood from your heart to the rest of your body. Risk factors for developing DVT include surgery, hospitalization for medical illness, major trauma (especially a long bone fracture of the leg), cancer and neurological disorders that cause leg weakness. When a blood clot (thrombus) develops in a vein, the danger is that it will break loose and travel to your lungs, where it can become stuck. This serious condition is known as a pulmonary embolism and, in some cases, the result is sudden death. It's estimated that each year about 1 million Americans have a DVT or pulmonary embolism episode; about one-third are fatal. Dr. Heit discusses the need to examine the role of genetics in DVT and the need for increased awareness of DVT: For more information from Mayo Clinic on DVT, click here: http://mayoclinic.com/health/deep-vein-thrombosis/DS01005 |
 | Thrombosis Associated with Coronary Drug-Eluting Stents In December 2006, FDA convened an advisory panel to evaluate what is known about the risk of thrombosis in patients with drug-eluting stents. These stents, the Cypher and Taxus, were approved by FDA because they can reduce the incidence of vessel restenosis when compared with bare metal stents. But information collected after they were marketed showed that both of them are associated with an increased risk of thrombosis after one year compared with bare metal stents. This presents a benefit vs. risk situation for the healthcare provider and the patient. The device can reduce restenosis rates and thereby avoid subsequent surgery, but it can also increase the risk of serious clotting. The risk is small (from less than 1 percent to about 5 percent) but when a thrombus occurs it can lead to sudden death or acute MI. When the panel looked at the risk of thrombosis in patients with these stents, they found that this risk varies depending on how the device is used. When the stents were used in clinically stable patients with lesions less than 28-30 mm (i.e., the criteria specified in the product labeling), the benefits of the device in reducing restenosis could outweigh the thrombosis risk. But when the stents were used "off label" (i.e., in patients with more complex lesions or various co-existing conditions) the risk of thrombosis was higher. The panel emphasized the importance of giving these patients antiplatelet medication after the surgery to reduce the risk of clotting. The panel also noted that current guidelines suggest giving these patients the antiplatelet therapy for 12 months after surgery, provided the patient is not at high risk of bleeding. In addition, the panel recommended that larger, longer studies be done to determine how long the risk of thrombosis persists after surgery and how long antiplatelet therapy needs to be continued. Until these studies are completed, there are a few patient management issues that clinicians might want to consider. First, there is the finding that the risk of thrombosis is higher when the device is used "off-label". Second, clinicians should understand importance of keeping patients on antiplatelet therapy for a long enough time, and educating them not to discontinue this therapy without medical consultation. Patients who cannot comply with long-term antiplatelet therapy may not be good candidates for a drug eluting stent. The same holds true for patients who have planned surgical procedures that would require discontinuing this therapy. |
العربية
中国
Français
Deutsch
Ελληνική
हिन्दी
Italiano
日本語
Português
Русский
Español
